Relmada Therapeutics (RLMD) Non Operating Investment Income (2020 - 2026)
Relmada Therapeutics (RLMD) reported Non Operating Investment Income of -$540097.0 for Q1 2026, down 446.81% year-over-year from $155731.0 in Q1 2025, and down 390.3% quarter-over-quarter from $186045.0 in Q4 2025.
Relmada Therapeutics (RLMD) Non Operating Investment Income (2020 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 7 years of Non Operating Investment Income data on file, last reported at -$540097.0 in Q1 2026.
- Non Operating Investment Income for Q1 2026 came in at -$540097.0, down 446.81% year-over-year; the trailing twelve-month figure through Mar 2026 was -$297574.0 (down 366.28% YoY), and the FY2025 annual result was $398255.0, up 5813.21% from the prior year.
- Non Operating Investment Income eased to -$540097.0 in Q1 2026 per RLMD's latest filing, from $186045.0 in the prior quarter.
- Over five years, Non Operating Investment Income peaked at $3.8 million in Q4 2023 and troughed at -$1.8 million in Q1 2022.
- A 5-year average of -$31301.8 and a median of -$45465.0 in 2024 frame the typical range for Non Operating Investment Income.
- The sharpest annual moves came in 2022 and 2023: Non Operating Investment Income sank 1192.3% in 2022, then jumped 1260.84% in 2023.
- A 5-year view of Non Operating Investment Income shows it stood at -$323120.0 in 2022, then jumped by 1260.84% to $3.8 million in 2023, then sank by 107.39% to -$277068.0 in 2024, then soared by 167.15% to $186045.0 in 2025, then slumped by 390.3% to -$540097.0 in 2026.
- Business Quant data shows RLMD's Non Operating Investment Income at -$540097.0 in Q1 2026, $186045.0 in Q4 2025, and $70275.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 230,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | -540,097.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -540,097.00 |
| Mar 31, 2026 | -540,097.00 |
| Dec 31, 2025 | 186,045.00 |
| Dec 31, 2025 | 186,045.00 |
| Sep 30, 2025 | 70,275.00 |
| Sep 30, 2025 | 70,275.00 |
| Jun 30, 2025 | -13,797.00 |
| Jun 30, 2025 | -13,797.00 |
| Mar 31, 2025 | 155,731.00 |
| Mar 31, 2025 | 155,731.00 |
| Dec 31, 2024 | -277,068.00 |
| Dec 31, 2024 | -277,068.00 |
| Sep 30, 2024 | 278,555.00 |
| Sep 30, 2024 | 278,555.00 |
| Jun 30, 2024 | -45,465.00 |
| Jun 30, 2024 | -45,465.00 |
| Mar 31, 2024 | 50,713.00 |
| Mar 31, 2024 | 50,713.00 |
| Dec 31, 2023 | 3.75 Mn |
| Dec 31, 2023 | 3.75 Mn |